PTC Therapeutics, Inc.

489 articles with PTC Therapeutics, Inc.

• PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results

  7/15/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, July 29, 2021 , at 4:30 p.m. (ET) after the closing of the market.

• Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone

  6/24/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical benefit of EMFLAZA® (deflazacort) over prednisone for the treatment of Duchenne muscular dystrophy (DMD).

• Evrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy

  6/23/2021

  PTC Therapeutics, Inc. announced that Evrysdi™ was approved in Japan by the Japanese Ministry of Health, Labor and Welfare for the treatment of spinal muscular atrophy.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 15, 2021

  6/15/2021

  PTC Therapeutics, Inc. announced that on June 11, 2021 it approved non-statutory stock options to purchase an aggregate of 118,350 shares of its common stock and 30,835 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 66 new employees.

• Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi™ in RAINBOWFISH

  6/11/2021

  PTC Therapeutics, Inc. announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomatic infants with spinal muscular atrophy treated with Evrysdi were able to reach motor milestones such as sitting without support, rolling, crawling, standing unaided and walking independently.

• Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics' Board of Directors

  6/9/2021

  Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health Service, a $6 billion division of the U.S. Department of Health and Human Services and system of hospitals providing healthcare to more than two million Native Americans in the United States.

• PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia

  5/26/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation (ODD) for PTC923 for the treatment of patients with hyperphenylalaninemia. Phenylketonuria (PKU) accounts for 98% of all hyperphenylalaninemia cases and is a metabolic condition that can lead to cognitive disabilities and seizures

• PTC Therapeutics to Participate at Upcoming Virtual Investor Conference

  5/19/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conference: William Blair 41 st Annual Growth Stock Conference Wednesday, June 2 nd at 3:40 p.m. ET

• New Data Shows Devastating Impact of AADC Deficiency on Caregivers

  5/17/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data from the first study on the impact of caring for a child with the ultra-rare genetic disorder, aromatic L-Amino acid decarboxylase deficiency (AADC-d).

• PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results

  5/4/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2021.

• PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences - Apr 27, 2021

  4/27/2021

  PTC Therapeutics, Inc. announced that management will present a company overview at the following conferences

• PTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results

  4/20/2021

   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2021 financial results and provide an update on the company's business and outlook on Tuesday, May 4, 2021 at 4:30 p.m. (ET) after the closing of the market.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 19, 2021

  4/19/2021

  PTC Therapeutics, Inc. announced that on April 13, 2021 it approved non-statutory stock options to purchase an aggregate of 75,085 shares of its common stock and 33,740 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 79 new employees.

• Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™

  4/15/2021

  PTC Therapeutics, Inc. announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1 spinal muscular atrophy treated with Evrysdi™ obtained increases in survival and sustained improvements in achieving key motor milestones, including head control, sitting, rolling over, and further developing towards acquiring the ability to stand, and walk.

• PTC Therapeutics Launches the PTC Pinpoint Direct™ Program for Patient-Initiated Genetic Testing

  4/14/2021

  - Provides easier access to genetic testing for patients with symptoms or diagnosis of cerebral palsy at no charge -

• PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar

  4/7/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T.

• PTC Therapeutics Received Gallup's Don Clifton Strengths-Based Culture Award

  4/7/2021

   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 "Don Clifton Strengths-Based Culture Award" from Gallup.

• PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™

  4/1/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi™ (risdiplam) in the European Union under its License and Collaboration Agreement with Roche.

• PTC Therapeutics Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular Atrophy

  3/30/2021

  PTC Therapeutics, Inc. announced that the European Commission has granted marketing authorization to Evrysdi™ for the treatment of spinal muscular atrophy in patients 2 months and older.

• Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients

  3/16/2021

  Patients and caregivers reported a greater ability to complete activities of daily livingwith increased independence